Cite
HARVARD Citation
Yoh, K. et al. (2016). A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung cancer. pp. 186-193. [Online].